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Abstract 
 
Although inhibition of the epidermal growth factor receptor (EGFR) is a plausible 
therapy for malignant gliomas that, in vitro, enhances apoptosis, the results of clinical 
trials have been disappointing. The mammalian target of rapamycin (mTOR) is a 
serine/threonine kinase that integrates starvation signals and generates adaptive 
responses that aim at the maintenance of energy homeostasis. Antagonism of mTOR 
has been suggested as a strategy to augment the efficacy of EGFR inhibition by 
interfering with deregulated signalling cascades downstream of Akt. Here we 
compared effects of antagonism of mTOR utilizing rapamycin or small hairpin RNA 
(shRNA)-mediated gene silencing to those of EGFR inhibition or combined inhibition 
of EGFR and mTOR in human malignant glioma cells. In contrast to EGFR inhibition, 
mTOR antagonism neither induced cell death nor enhanced apoptosis induced by 
CD95 ligand (CD95L) or chemotherapeutic drugs. However, mTOR inhibition 
mimicked the hypoxia-protective effects of EGFR inhibition by maintaining ATP levels. 
These in vitro experiments thus challenge the current view of mTOR as a 
downstream target of Akt that mediates antiapoptotic stimuli. Under the conditions of 
the tumour microenvironment, metabolic effects of inhibition of EGFR, Akt and mTOR 
may adversely affect outcome by protecting the hypoxic tumour cell fraction. 
 
Abstract: 198 words 
 
Key words: mTOR, EGFR, glioma, hypoxia, metabolism 
 
Abbreviations:  
4E-BP1, eukaryotic translation initiation factor 4E binding protein 1 
Page 4 of 58
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 817 2040 ext. 167
Brain
For Peer Review
 
4 
CD95L, CD95 ligand 
EGFR, epidermal growth factor receptor  
eIF4E, eukaryotic translation initiation factor 4E 
HIF-1 α, hypoxia inducible factor-1 α 
LDH, lactate dehydrogenase 
mTOR, mammalian target of rapamycin 
p42/44 MAPK, p42/44 mitogen-activated protein kinase 
PI3K, phosphatidyl-inositole-3-phosphate kinase 
RPS6, ribosomal protein S6 
S6K1, ribosomal protein S6 kinase 1 
shRNA, small hairpin RNA 
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Introduction 
 
Patients with glioblastoma face a grim prognosis with a median survival of less than 
one year in unselected cohorts (Ohgaki et al., 2004). Novel therapeutic approaches 
are therefore urgently needed. Targeting signalling downstream of activated growth 
factor receptors is currently considered one of the most promising approaches. 
Specifically, the EGFR is amplified or activated in the majority of primary 
glioblastomas and can be regarded as one of the most plausible targets for molecular 
therapy (Kleihues et al., 2000). EGFR signalling sustains many key features of the 
neoplastic phenotype, e.g. it enhances cell autonomous growth, invasion and 
angiogenesis and confers protection from growth inhibitory and proapoptotic stimuli 
(Mendelsohn, 2002; Steinbach and Weller, 2002). 
Clinical trials with small molecule kinase inhibitors of the EGFR in malignant glioma 
patients, however, have produced disappointing results (Van Den Bent et al., 2007). 
Insufficient suppression of the intracellular signalling cascade downstream of EGFR 
has been suggested as an important cause for the failure of EGFR inhibitors. 
Phosphorylation of Akt, in particular, represents a negative predictive marker for the 
response of malignant glioma patients to EGFR inhibitors (Haas-Kogan et al., 2005). 
The serine/threonine kinase mTOR is a key mediator of phosphatidyl-inositole-3-
phosphate kinase (PI3K) and Akt signalling. It integrates growth-inhibitory signals 
such as deprivation of glucose and amino acids, ATP depletion, hypoxia and lack of 
growth factors (Wullschleger et al., 2006) in order to generate adaptive cellular 
responses primarily by altering the translation of specific proteins. Deregulated 
mTOR signalling sustains proliferation of malignant cells by antagonizing these 
physiological starvation signals (Peng et al., 2002). It therefore appears plausible that 
the commonly observed activation of mTOR signalling in glioblastoma (Choe et al., 
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2003) contributes to the typical pattern of glioblastoma pathology with necrotic cores 
and aggressive growth at the tumour margins. The translational effects of mTOR 
signalling are mediated by phosphorylation of its two direct target molecules, 
eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and ribosomal 
protein S6 kinase 1 (S6K1), at specific sites. Phosphorylation of 4E-BP1 occurs 
stepwise and relieves its repression of eukaryotic initiation factor 4E (eIF4E) (Hara et 
al., 1997), resulting in activation of translation initiation. In this process, 
phosphorylation of the residues Thr37/46 is the initial step in 4E-BP1 phosphorylation. 
It is also a prerequisite for phosphorylation of residues Thr70 and Ser65, whose 
phosphorylation alone is not sufficient to block binding to eIF4E (Gingras et al., 2001). 
The different phosphorylation states of 4E-BP1 are evidenced by 3 differently 
migrating bands in immunoblot analyses: a fastest migrating hypophosphorylated α 
band, a β band of intermediate mobility and a slowest migrating hyperphosphorylated 
γ band. Thr37/46 phosphorylated 4E-BP1 can be detected in all 3 bands and is 
relatively insensitive to serum deprivation and mTOR inhibition. However, the pattern 
of phosphorylated 4E-BP1 shifts to the hypophosphorylated faster migrating bands 
following mTOR inhibition (Brunn et al., 1997). Phosphorylation of S6K1 results in 
activation of its kinase activity and phosphorylation of ribosomal protein S6 (RPS6), 
which, among other proteins, regulates translation of ribosomal proteins and 
elongation factors (Hay and Sonenberg, 2004). With the availability of rapamycin and 
related drugs that specifically inhibit mTOR signalling, considerable interest has been 
generated to investigate antagonism of mTOR as an anti-glioma strategy (Hidalgo 
and Rowinsky, 2000; Huang and Houghton, 2001). In preclinical models, mTOR 
inhibition has been reported to result in apoptotic and non-apoptotic cell death (Rao 
et al., 2005; Takeuchi et al., 2005), cell cycle arrest (Tanaka et al., 2007) and 
Deleted: first 
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decreased angiogenesis (Del Bufalo et al., 2006). mTOR inhibition is particularly 
effective against some cell lines with mutant PTEN (Neshat et al., 2001).  
Augmentation of the efficacy of EGFR inhibition by mTOR inhibition therefore 
appears plausible (Doherty et al., 2006; Reardon et al., 2006). However, we have 
previously identified an undesirable consequence of interference with EGFR function 
that offers an alternative explanation for the poor clinical performance of EGFR 
antagonistic strategies and may also adversely affect the efficacy of mTOR inhibition. 
Altered cellular metabolism and energy expenditure, which are enhanced by EGFR 
signalling, are at the core of this phenomenon which results in the protection of 
malignant glioma cells from hypoxia when EGFR is inhibited (Steinbach et al., 2004; 
Steinbach et al., 2005). In these experiments, EGFR inhibition and resistance 
towards hypoxia were associated with decreased phosphorylation of the mTOR 
target RPS6. Given the physiological role of mTOR in the regulation of metabolic 
demands, these results suggested that EGFR inhibition confers protection against 
hypoxia in a mTOR-dependent fashion. We here report the results of a 
comprehensive analysis of cell-autonomous effects of mTOR antagonism on CD95L-, 
chemotherapy- and hypoxia-induced cell death in human malignant glioma cells 
employing rapamycin and shRNA-mediated gene suppression of mTOR 
(Brummelkamp et al., 2002) and a comparison of mTOR inhibition with EGFR 
inhibition or combined inhibition of mTOR and EGFR. 
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Materials and Methods 
 
Reagents and cell lines 
U0126, an inhibitor of MEK 1 and 2, the PI3K inhibitor LY294002, Akt inhibitor VIII 
and EGF were purchased from Calbiochem (San Diego, CA, USA), the EGFR 
inhibitor PD153035 and the mTOR inhibitor rapamycin from Tocris Cookson (Bristol, 
UK), erlotinib and IGF-1 from Roche (Mannheim, Germany). Tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) was purchased from PeproTech (Rocky 
Hill, NJ, USA). LNT-229 (PTEN wildtype) and U87MG (PTEN mutant) human 
malignant glioma cell lines have been described (Ishii et al., 1999; Steinbach et al., 
2004; Steinbach et al., 2003). The generation of primary cell cultures has also been 
previously described (Bahr et al., 2003). Established glioma cell lines and primary 
cultures were maintained in Dulbecco’s modified eagle medium (DMEM) containing 
10% foetal calf serum (FCS) (Biochrom KG, Berlin, Germany), 100 IU/ml penicillin 
and 100 mg/ml streptomycin (Life Technologies, Karlsruhe, Germany). pSUPER puro 
transfected cells were maintained in medium containing 2 µg/ml puromycin (Sigma, 
Deisenhofen, Germany). Lomustine (CCNU, 1-[2-chloroethyl]-3-cyclohexyl-1-
nitrosourea) and vincristine as well as all other chemicals not specified below were 
purchased from Sigma. 
 
Immunoblot analysis 
Immediately after incubation, cells were washed with ice-cold PBS and harvested into 
ice-cold PBS containing protease inhibitors. Cellular lysates were prepared as 
described (Steinbach et al., 2003) and subjected to SDS-PAGE analysis. Membranes 
were probed with antibodies to phospho-p90RSK (P-p90RSK) (Ser380), phospho-Akt 
(P-Akt) (Ser473), phospho-p42/44 mitogen-activated protein kinase (P-p42/44 MAPK) 
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(Thr202/Tyr204), phospho-RPS6 (P-RPS6) (Ser235/236) and eIF4E (employed here 
as internal standard for equal protein loading) utilizing the Pathscan Multiplex 
Western Cocktail I or with antibodies to P-Akt  (Ser473), Akt, P-p42/44 MAPK 
(Thr202/Tyr204), phospho-S6K1 (P-S6K1) (Thr389), S6K1, phospho-4E-BP1 (P-4E-
BP1) (Thr37/46), 4E-BP1 and mTOR all purchased from Cell Signaling (Beverly, MA, 
USA). The antibody to hypoxia inducible factor (HIF)-1 α was purchased from R&D 
Systems (Minneapolis, MN, USA) and the antibody to cyclin D1 and p42/44 MAPK 
was from Santa Cruz Biotechnology (Santa Cruz, Ca, USA). The secondary anti-
rabbit and anti-goat antibodies were purchased from Santa Cruz Biotechnology. 
Enhanced chemiluminescence (ECL+) (Amersham, Little Chalfont, UK) was used for 
detection. 
 
Cell growth and viability assays 
Cell growth was assessed by crystal violet staining as previously described (Roth et 
al., 1997). Further cultures derived from primary glioblastoma surgery specimens 
were pulsed with [methyl-3H]thymidine (1 µCi; Amersham) on day 2 and collected 16 
h later using a cell harvester (Tomtec, Hamden, CT). Incorporated radioactivity was 
bound to a glass fiber filtermat (Wallac, Turku, Finland). The filtermat was wetted with 
Ultima Gold Scintillation Cocktail (Packard, Dreieich, Germany) and radioactivity was 
determined in a Wallac 1450 Microbeta Plus Liquid Scintillation Counter. For cell 
viability analysis, the cells were washed with ice-cold PBS, stained with 5 µg/ml 
propidium iodide (PI) in PBS and analysed by flow cytometry employing a DAKO 
CyAn flow cytometer and Summit 4.2. software. Alternatively, cell viability was 
analysed by lactate dehydrogenase (LDH) release assays (Steinbach et al., 2004). 
CD95L was obtained from the supernatant of CD95L-transfected N2A murine 
neuroblastoma cells (Roth et al., 1997). For the detection of chemotherapy-induced 
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cell death, the cells were plated on 96 well plates (Falcon, Becton-Dickinson) at 1.5 x 
104/well and allowed to attach overnight. Then the cells were incubated with or 
without rapamycin and chemotherapeutics for 72 h in serum-free medium and 
stained with crystal violet. 
 
Induction of hypoxia 
Hypoxia was induced by incubating cells in Gas Pak pouches for anaerobic culture 
(Becton Dickinson, Heidelberg, Germany) (Steinbach et al., 2003). Briefly, the cells 
were plated on 96 well plates at 2 x 104/well or petri dishes of various sizes and 
allowed to attach overnight. Then the cells were incubated in serum-free DMEM 
without glucose (Gibco BRL, Basel, Switzerland) adjusted to 2 mM glucose under 
normoxia or hypoxia for the indicated time periods. Equal cell densities were ensured 
by crystal violet staining when comparing vehicle and rapamycin pre-incubated cells 
as wells as LNT-229 puro and LNT-229 mTORsh cells. 
 
Generation of LNT-229 mTORsh knockdown cells 
The pSUPER plasmid was obtained from R. Agami (Amsterdam, The Netherlands). A 
puromycin cassette was inserted into the NaeI site. The mTOR-specific 
oligonucleotide sequences GATCCCC ACTTCGAAGCTGTGCTACA ttcaagaga 
TGTAGCACAGCTTCGAAGT TTTTTGGAAA and TCGATTTCCAAAAA 
ACTTCGAAGCTGTGCTACA tctcttgaa TGTAGCACAGCTTCGAAGT GGG 
[nucleotides (nt) 5,469-5,487] were obtained from Biomers.net (Ulm, Germany) and 
cloned into the BglII and SalI sites of pSUPER. The mTOR-specific parts of the 
sequences are underlined. For the generation of stable mTORsh transfectants, 
pSUPER puro control or mTORsh plasmids were introduced using FuGene6 
transfection reagent (Roche). 
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ATP assay 
Immediately after normoxic or hypoxic incubation, the plates were placed on ice and 
the cells were pelleted by centrifugation and lysed in ATP releasing reagent (Sigma). 
The ATP concentration was determined by luciferase assay with the CLS II kit 
(Boehringer, Mannheim, Germany) (Steinbach et al., 2003). 
 
JC-1 assay 
Following treatment as indicated, the cells were washed in PBS and incubated for 15 
min in JC-1 staining reagent (Biocarta, Hamburg, Germany) at 37°C. Then the cells 
were washed once in assay buffer, resuspended in PBS and analysed by flow 
cytometry. 
 
Glucose assay 
Immediately after hypoxia the cells were pelleted by centrifugation and the 
supernatant was assayed for glucose employing the Gluco-quant kit (Roche).  
 
Statistical analysis 
Quantitative data obtained for cell density by crystal violet, LDH-release, glucose and 
ATP concentrations are expressed as mean and SD as indicated. P-values for cell 
density by crystal violet, LDH-release, glucose and ATP concentration were derived 
from two-tailed Student's t-tests. Values of P > 0.05 were considered not significant 
(n.s.), values of P < 0.05 and P < 0.01 were considered significant and highly 
significant (Excel, Microsoft, Seattle, WA, USA). When multiple tests were performed 
significance levels (α values) were adjusted using the Holm-Bonferroni method. 
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Results 
 
Preferential inhibition of the p70 isoform of S6K1 by rapamycin in human malignant 
glioma cells 
To establish the specific pattern of rapamycin action in human malignant glioma cells, 
PTEN wildtype LNT-229 or PTEN mutant U87MG cells were exposed to rapamycin. 
Phosphorylation of the 70 kD isoform of the direct mTOR target S6K1,  which 
correlates with its activity (Harris and Lawrence, 2003), was inhibited by rapamycin in 
a concentration-dependent fashion and abolished at a concentration of 100 nM in 
both cell lines (Fig. 1). Therefore, this concentration which also corresponds to the 
effective rapamycin concentrations required in other malignant glioma and non-
glioma cell lines (Peng et al., 2002; Tanaka et al., 2007; Wei et al., 2008), was used 
as a standard for subsequent experiments. Of note, the 85 kD isoform of S6K1 which 
is located in the nucleus and known to be less abundant than the 70 kD isoform in 
some cell lines (Reinhard et al., 1994), was much less sensitive to inhibition by 
rapamycin, particularly in U87MG cells.  
 
 
CD95L- and chemotherapy-induced cell death: dissociation of the effects of EGFR 
inhibition and mTOR inhibition 
EGFR-dependent signalling is a major determinant of susceptibility towards death 
ligand/CD95L- and chemotherapy-induced cell death in human malignant glioma 
cells. It has been suggested that the proapoptotic properties of EGFR inhibitors are 
mediated by decreased mTOR signalling. To compare the effects of mTOR inhibition 
with those of inhibition of EGFR, PI3K or MEK, LNT-229 and U87MG cells were 
exposed to rapamycin, PD153035, LY294002 and U0126 alone or in combination. 
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The specificity of pathway inhibition was assessed by immunoblot analysis for 
phosphorylated p90RSK, Akt, p42/44 MAPK, RPS6, 4E-BP1 and total eIF4E or 4E-
BP1 as a loading control (Fig. 2A). In PTEN wildtype LNT-229 cells, only the EGFR 
inhibitor PD153035 abolished RPS6 phosphorylation when administered alone (Fig. 
2A). In contrast, rapamycin, LY294002 and U0126 only partially inhibited the 
phosphorylation of RPS6. Co-inhibition of PI3K and MEK with LY294002 and U0126 
mimicked the effects of PD153035 on P-RPS6, suggesting that both branches of 
EGFR signalling, PI3K and MEK, must be inhibited for abrogation of RPS6 
phosphorylation. Accordingly, RPS6 phosphorylation was still detectable, albeit at a 
much lower level, in S6K knockout cells (Pende et al., 2004) and RPS6 can also be 
phosphorylated by p90RSK (Roux et al., 2007). Thus, dual mechanisms originating 
from MEK as well as from mTOR regulate the indirect mTOR target RPS6. In U87MG 
cells, rapamycin was the most effective agent for RPS6 inhibition, whereas 
PD153035 and U0126 had no effect (Fig. 2A). The inefficient inhibition of RPS6 
phosphorylation by PD153035 is plausible given that U87MG cells lack functional 
PTEN (Ishii et al., 1999). No agent alone abrogated Thr37/46 4E-BP1 
phosphorylation with roughly equivalent effects of rapamycin, PD153035 and 
LY294002 in LNT-229 and of rapamycin and LY294002 in U87MG cells. The most 
pronounced effects on 4E-BP1 phosphorylation were achieved by combining 
rapamycin with PD153035 or LY294002 and the effect of these inhibitors was most 
pronounced in the slowest migrating γ band of 4E-BP1.  
The cell death-promoting potential of mTOR inhibition was then assessed by 
exposing LNT-229 or U87MG cells to CD95L in the presence of rapamycin, 
PD153035, LY294002 or U0126 alone or combined as indicated. (Fig. 2A, lower 
panel). Rapamycin alone sensitized neither LNT-229 nor U87MG cells to CD95L. 
Rapamycin also failed to induce synergistic or additive cytotoxic effects when 
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combined with PD153035, LY294002 or U0126 (Fig. 2A, bottom panel). In LNT-229 
cells PD153035 was the only agent which substantially sensitized to CD95L. While 
both substances alone did not modulate CD95L-induced cell death, the combination 
of LY294002 and U0126 also sensitized the cells, although to a lesser degree than 
PD153035. Notably, also the combination of rapamycin with U0126 which abolished 
RPS6 phosphorylation in the immunoblot analysis was inefficient. Largely similar 
results were obtained in U87MG cells (Fig. 2A, bottom panel) with PD153035 as the 
most potent sensitising agent and rapamycin failing to show any effect alone or in 
any of the investigated combinations. Although after correction for multiple testing 
only PD153035, PD153035 plus rapamycin and LY294002 plus U0126 achieved 
significance in U87MG cells. In parallel experiments with LNT-229 and U87MG cells, 
CD95L-induced cell death in the presence of rapamycin or PD513035 was analysed 
by LDH release with similar results, indicating that the CD95L-mediated effect is not 
due to an inhibition of proliferation rather than cell death (data not shown). Since 
mTOR exerts its effect partially through modulation of mRNA translation, we asked 
whether pretreatment of glioma cells with rapamycin, to allow for the time necessary 
to reach the new levels of target proteins, alters susceptibility to CD95L-mediated 
apoptosis. Again, rapamycin was ineffective (data not shown). Notably, exposure to 
rapamycin up to 24 h did not induce growth inhibition or cell death in any of these 
experiments as assessed by crystal violet staining or LDH release assays.  
Concerning inhibitor specificity, we have previously shown that the EGFR inhibitor 
AG1478 has similar effects as PD153035 both with regard to sensitivity to apoptosis 
(Steinbach et al., 2002) and protection from hypoxia-induced cell death (Steinbach et 
al., 2004). To delineate consequences for clinical practise, we performed additional 
experiments with the clinically used EGFR inhibitor erlotinib (supplementary Fig. 
S1A), We also performed experiments with lower inhibitor concentrations of the PI3K 
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and MEK inhibitors (5 µM LY294002 and 10 µM U0126) since their necessary 
concentrations remain controversial, with similar results (compare Fig. 2A and 
supplementary Fig. S1C).  
To further clarify the level of EGFR-dependent signal transduction that mediates the 
proapoptotic consequences, we performed experiments with the Akt-specific inhibitor 
Akt inhibitor VIII which blocks Akt phosphorylation and activation by an allosteric 
mechanism (DeFeo-Jones et al., 2005). Phosphorylation of Akt was abolished with 1 
µM Akt inhibitor VIII (supplementary Fig. S2A). Akt inhibitor VIII sensitized LNT-229 
cells towards CD95L- as well as towards TRAIL-mediated apoptosis (supplementary 
Fig. S2B, C).  
Rapamycin is currently investigated in combination with several chemotherapeutics, 
including vincristine, VP-16, cisplatin and others for various malignancies 
(Haritunians et al., 2007). To test whether rapamycin might enhance the cytotoxicity 
of chemotherapeutic drugs administered for the treatment of patients with malignant 
glioma, we co-incubated LNT-229 cells with rapamycin and CCNU or vincristine (Fig. 
2B). The cytotoxic effects of these drugs were not altered by co-incubation with 
rapamycin. It has recently been reported that rapamycin can cause activation of Akt 
and p42/44 MAPK through relieving feedback inhibitory mechanisms. To further 
address this issue, we performed immunoblot experiments with LNT-229 and U87MG 
cells after up to 24 h of exposure to rapamycin. However, rapamycin did not enhance 
Akt phosphorylation (Ser473) at any timepoint (supplementary Fig. S3A, B and Fig. 
4A, lanes 2, 3). Stably transfected mTORsh cells also have unaltered P-Akt levels 
(Fig. 5D, lanes 1-4). Therefore, the feedback inhibition of Akt that has been found in 
the PTEN wild type prostate cancer cell line DU-145 and the breast cancer cell line 
MCF-7 (O'Reilly et al., 2006) is not present in LNT-229 or U87MG glioblastoma cells. 
We also failed to detect an increase in p42/44 MAPK phosphorylation in cells 
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exposed to rapamycin (supplementary Fig. S3A, B and Fig. 4A, lanes 2,3) and 
mTORsh cells (Fig. 5D, lanes 1-4) in contrast to the findings reported in other tumor 
types exposed to mTOR inhibitors (Carracedo et al., 2008).  
 
Rapamycin causes growth inhibition in human malignant glioma cells but is not 
cytotoxic 
Rapamycin exerts antiproliferative effects in a variety of human tumour cell lines 
(Easton and Houghton, 2006). Cytotoxic effects have also been reported in the 
human malignant glioma cell lines U87MG, T98G and U373MG (Takeuchi et al., 
2005). To differentiate growth inhibitory from cytotoxic effects of rapamycin, cell 
growth and viability were assessed in parallel by crystal violet staining and flow 
cytometry for PI uptake in cells exposed to rapamycin or vehicle. In growth curves 
established in the presence of rapamycin, cell growth was decreased both in serum-
free medium and medium containing 10% FCS in the cell lines LNT-229 and U87MG 
(Fig. 3A, B, left side). In the SV40-transformed astrocytic cell line SV-FHAS, the 
growth inhibitory effect of rapamycin was also potent with a cell growth of less than 
50% in relation to the vehicle control in medium containing 10% FCS (data not 
shown). Cell viability was unaffected by exposure to rapamycin for up to 72 h (Fig. 3A, 
B, right side). Similar results were obtained in PTEN mutant T98G human malignant 
glioma cells and in long-term cultures with regular administration of rapamycin for 
several weeks (data not shown). PTEN wildtype LNT-229 and PTEN mutant U87MG 
and T98G cells showed similar sensitivity to rapamycin-induced growth inhibition 
without detection of rapamycin cytotoxicity. Also, similar growth inhibitory effects of 
rapamycin in the absence of cytotoxicity were observed in all primary cultures of 
human malignant gliomas investigated (Fig. 3C, supplementary Fig. S4A). Since the 
concomitant PI-staining did not reveal changes in the number of dead cells, the 
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observed effects are likely due to changes in proliferation. This is also corroborated 
by reduced [methyl-3H]thymidine incorporation in 4 investigated primary glioblastoma 
cultures (supplementary Fig. S4B). 
 
 
Hypoxia inhibits mTOR signalling and inhibition of mTOR signalling by rapamycin 
protects human malignant glioma cells from hypoxia-induced cell death 
Hypoxia suppresses mTOR activity via the proteins REDD and TSC1/TSC2 
(Brugarolas et al., 2004). This mechanism is considered an adaptive response 
allowing cells to survive under hypoxic and nutrient-deprived conditions by 
decreasing mTOR-dependent metabolic demands. To explore hypoxia-induced 
alterations of mTOR signalling, we employed a paradigm of hypoxia with partial 
glucose depletion and a defined mechanism of energy-dependent cell death of 
mainly necrotic features (Steinbach et al., 2004; Steinbach et al., 2003). The activity 
of mTOR targets was analysed by phospho-specific immunoblots. Under normoxic 
conditions, glucose restriction and serum withdrawal decreased the phosphorylation 
of Akt, RPS6 and S6K1 and shifted the pattern of the 4E-BP1 isoforms towards the 
lower hypophosphorylated α and β bands in LNT-229 cells (Fig. 4A). Rapamycin 
further suppressed S6K1 phosphorylation. Hypoxia had dramatic effects on mTOR 
signalling, abolishing phosphorylation of RPS6 and S6K1 and shifting 4E-BP1 
phosphorylation utmost towards the lowest α band. Hypoxia also decreased the 
phosphorylation of p42/44 MAPK and this effect was enhanced by PD153035 (Fig. 
4A). We had previously hypothesized that the protection from hypoxia conferred by 
inhibition of EGFR signalling is mediated by decreased mTOR activity (Steinbach et 
al., 2004). We therefore exposed LNT-229 cells to hypoxia in the presence of 
rapamycin or PD153035. Hypoxia-induced cell death was indeed reduced by 
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rapamycin (Fig. 4B). However, rapamycin was less potent than PD153035, indicating 
that PD153035 might exert its hypoxia-protective functions only partially via mTOR. 
Note that while PD153035 was cytotoxic under normoxic conditions, rapamycin was 
not (Fig. 4B, left graph). The hypoxia-protective effect of rapamycin became apparent 
at concentrations as low as 1 nM, with largely similar effects of concentration of 10 to 
1000 nM in LNT-229 cells (supplementary Fig. S5A). Thus, low concentrations of 
rapamycin that are achieved in glioblastoma in vivo (Cloughesy et al., 2008) have the 
potential to protect glioblastoma cells from hypoxia while 1000-fold higher 
concentrations fail to induce cell death. The autophagy inhibitor 3-methyl-adenine did 
not abrogate PD153035 or rapamycin-mediated protection from hypoxia-induced cell 
death (data not shown). Also in ultrastructural analyses autophagy was not 
detectable in our model of hypoxia-induced cell death (Steinbach et al., 2005). 
Notably, rapamycin also protected cells derived from 2 out of 3 tested primary 
glioblastoma cultures from hypoxia-induced cell death, whereas PD153035 was 
effective in all (supplementary Fig. S5B). Furthermore, inhibition of Akt conferred 
protection from hypoxia (supplementary Fig. S2D); erlotinib also protected LNT-229 
cells from hypoxia (supplementary Fig. S1B). Since mTOR exerts its effects in part 
via alterations of translation, the full impact of inhibition of mTOR may only become 
apparent when the levels of the target proteins have reached their (new) equilibrium. 
We therefore preincubated LNT-229 cells with rapamycin prior to exposure to 
hypoxia. Equal cell density in the differently preincubated cells was ensured by 
crystal violet staining prior to hypoxic conditioning and glucose restriction. 
Preincubation considerably enhanced the hypoxia-protective effect of rapamycin (Fig. 
4C).  
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shRNA-mediated gene silencing of mTOR confers protection from hypoxia-induced 
cell death 
Rapamycin exclusively inhibits the mTOR complex 1 (mTORC1), while the mTOR 
complex 2 (mTORC2), which contains mTOR in combination with different adaptor 
proteins, is resistant to rapamycin. To fully explore the role of the mTOR protein, we 
investigated the role of inhibition of mTOR using shRNA-mediated gene-silencing in 
stably transfected cells employing the pSUPER plasmid (Brummelkamp et al., 2002). 
The experiments were conducted with early-passage pooled clones. mTOR protein 
levels in LNT-229 cells stably transfected with the mTOR-directed sequence (LNT-
229 mTORsh) were approximately 20% of those in LNT-229 cells transfected with the 
empty control vector (LNT-229 puro) (Fig. 5A). To investigate how gene suppression 
of mTOR impairs mTOR-mediated signal transduction, we stimulated serum-starved 
LNT-229 puro or mTORsh cells with EGF and IGF-1 to test for stimulated 4E-BP1 
hyperphosphorylation (Brunn et al., 1997). After 24 h of incubation in serum-free 
medium, 4E-BP1 was detectable in both puro and mTORsh cells in the α and β 
bands evidencing a low phosphorylation state (Fig. 5B). In puro cells equal amounts 
of protein in the α and β bands were detectable, in mTORsh cells the extent of 
hypophosphorylation was more pronounced with more 4E-BP1 in the α than in the β 
band. 10 min incubation with EGF/IGF-1 led to an increase in phosphorylation of 4E-
BP1 and a resulting band shift in both puro and mTORsh cells. Puro cells exhibited 
almost equal distributions of α, β and γ bands, whereas α and β bands were still 
dominating in mTORsh cells indicating a lesser degree of 4E-BP1 phosphorylation. 
Similar results were obtained with an antibody that detects total 4E-BP1. Thus, 
phosphorylation of the mTOR target 4E-BP1 is suppressed in mTORsh cells, 
confirming the functionality of the gene suppression. Rapamycin addition to the 
serum-starved cells 1 h prior to stimulation with EGF and IGF-1 abolished 4E-BP1 
Page 20 of 58
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 817 2040 ext. 167
Brain
For Peer Review
 
20 
hyperphosphorylation as evidenced by the lacking γ band in cells incubated with 
EGF/IGF-1 (Fig. 5C). To test whether mTOR gene suppression has effects on EGFR-
dependent signalling in our hypoxia model, we compared the phosphorylation 
patterns of p90RSK, p42/44 MAPK, Akt and RPS6 using total eIF4E as a loading 
control (Fig. 5D). In contrast to LNT-229 puro cells, RPS6 phosphorylation was 
already abolished in mTORsh cells after 8 h incubation in serum-free medium 
containing 2 mM glucose under normoxia (Fig. 5D, lanes 3, 4), again indicating an 
impaired mTOR activity in mTORsh cells. In contrast, equal amounts of P-RPS6 were 
detectable in cells incubated in medium containing 10% FCS (Fig. 5D, lanes 1, 2).  
Thus, with supra-physiological stimulation of starvation-sensitive pathways, the 
residual mTOR activity in the mTORsh cells is sufficient to maintain RPS6 
phosphorylation. The phosphorylation patterns of the other investigated proteins not 
downstream of mTOR were comparable to those observed in LNT-229 wildtype cells 
(Fig. 4A). Of note, after 24 h incubation in serum-free medium without glucose 
deprivation LNT-229 mTORsh cells also exhibited a weaker RPS6 phosphorylation 
than puro control cells (data not shown). To test whether gene suppression of mTOR 
modulates the sensitivity to the chemotherapeutics CCNU or vincristine, we exposed 
LNT-229 puro or mTORsh cells to these drugs (Fig. 5E). Stable mTOR-knockdown 
cells were less sensitive to chemotherapy-induced cell death than puro control cells 
and rapamycin-treated cells. This effect may be explained either by long-term 
alterations of protein expression in the mTORsh cells or by a mTORC2-mediated 
mechanism. 
To characterize the effect of gene suppression of mTOR on proliferation, growth 
curves in serum-free medium and medium containing 10% FCS were established in 
LNT-229 mTORsh and puro cells in the absence or presence of rapamycin. Gene 
suppression of mTOR reduced proliferation to a similar degree as rapamycin (Fig. 
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5F). Rapamycin further decreased the proliferation of LNT-229 mTORsh cells. Similar 
effects were observed with medium containing 10% FCS (Fig. 5F, bottom panel). The 
additive growth-inhibitory effect may be due to inhibition of the residual mTOR protein 
in the mTORsh cells. Alternatively, suppression of the mTORC2 function in the LNT-
229 mTORsh cells may add to the effect of rapamycin. 
We then compared the sensitivity to hypoxia of LNT-229 mTORsh and puro cells. 
LNT-229 mTORsh cells were resistant to hypoxia-induced cell death (Fig. 5G). The 
protection conferred by inhibition of EGFR signalling with PD153035 was more 
pronounced than that of gene suppression of mTOR. In addition, PD153035, in 
contrast to rapamycin, enhanced the protection from hypoxia observed in mTORsh 
cells. Therefore, mTOR-independent signalling cascades downstream of the EGFR 
appear to contribute to the protective effect of PD153035. Protection from hypoxia-
induced cell death in LNT-229 mTORsh in comparison to LNT-229 puro cells was 
also detectable at the level of flow cytometric assessment of PI staining (data not 
shown).  
 
Antagonism of mTOR signalling preserves cellular ATP and mitochondrial integrity 
We have previously demonstrated that EGFR inhibition reduces glucose 
consumption, delays ATP depletion and preserves mitochondrial integrity during 
hypoxia (Steinbach et al., 2004). Similarly, in LNT-229 mTORsh cells as well as in 
rapamycin-pretreated LNT-229 cells, the hypoxia-induced depletion of ATP was 
delayed (Fig. 6A, B). Further, the percentage of cells with intact mitochondrial 
membrane potential after 16 h of hypoxic incubation was higher in LNT-229 mTORsh 
than in LNT-229 puro cells (Fig. 6C). Rapamycin preincubation, unlike EGFR 
inhibition, did not alter glucose consumption under hypoxic conditions (data not 
shown) in accordance with a previous report that rapamycin does not alter glucose 
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consumption in LN-229 cells under normoxia (Wei et al., 2008). Glucose 
consumption was also unchanged in LNT-229 mTORsh cells compared with LNT-229 
puro cells (Fig. 6D). These results indicate that antagonizing mTOR reduces energy 
demand, thus preserving cellular viability independent from glucose consumption. 
HIF-1 α is considered one mediator of mTOR-induced adaptive responses to hypoxia 
and HIF-1 α protein levels have been reported to decrease in response to mTOR 
inhibition with the rapamycin analogue CCI-779 in kidney cancer cells (Thomas et al., 
2006). Independent from its effects in angiogenesis, HIF-1 α adapts metabolic 
processes by altering the transcription of a large number of target genes (Semenza 
et al., 1994). Therefore we investigated HIF-1 α protein by immunoblot analysis in 
LNT-229 cells exposed to rapamycin or PD153035, both under normoxic and hypoxic 
conditions (Fig. 6E). Neither rapamycin nor PD153035 altered the induction of HIF-1 
α by hypoxia. HIF-1 α levels were also maintained in hypoxic LNT-229 mTORsh cells 
(Fig. 6F). 
Cycling cells are more sensitive to induction of apoptosis and have higher energy 
consumption. We therefore investigated the expression of the cell cycle regulator 
cyclin D1, another protein which that has been reported to be regulated in a mTOR-
dependent fashion (Averous et al., 2008). Rapamycin did not alter cyclin D1 protein 
levels (Fig. 6G). Thus, malignant glioma cells maintain the expression of molecules 
critical for proliferation, angiogenesis and metabolic adaptive function independently 
from mTOR. 
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Discussion: 
In an attempt to dissociate pathways responsible for two opposing major effects of 
EGFR signalling, we have explored to what extent mTOR mediates proapoptotic 
effects and metabolic hypoxia-protective effects of EGFR inhibition. 
We find that rapamycin is not cytotoxic to human malignant glioma cells as assessed 
by LDH release or PI assays. Of note, neither the viability of permanent cell lines nor 
that of primary cultures derived from glioma surgical specimens was affected by 
rapamycin (Fig. 3A-C, supplementary Fig. S4A). Further, whereas EGFR or Akt 
inhibition sensitized malignant glioma cells to the death ligand CD95L or TRAIL, 
rapamycin failed to sensitize these cells to CD95L, TRAIL or chemotherapeutic drugs 
such as CCNU or vincristine (Fig. 2A, B, supplementary Fig. S1A, S2B, C). Notably, 
the failure of rapamycin was not due to feedback activation of Akt or p42/44 MAPK 
which has been described in other tumour types (Carracedo et al., 2008; O'Reilly et 
al., 2006) (supplementary Fig. S3A, B). Therefore, dissociation of proapoptotic effects 
at the level of Akt remains the most plausible explanation for the absence of 
cytotoxicity of mTOR antagonistic strategies. 
These findings are corroborated by similar results observed in response to mTOR 
gene suppression (Fig. 5E, F). Stable mTOR-knockdown cells were even less 
sensitive to chemotherapy-induced cell death than puro control cells. This 
observation is in accordance with a recent report from Lee et al. who report that 
antagonism of mTOR in TSC-deficient fibroblasts protects these cells against DNA-
damage and etoposide by reducing p53-dependent cell death (Lee et al., 2007).  
Importantly, mTOR inhibition also did not induce synergistic effects when combined 
with inhibitors of EGFR, PI3K or MAPK, respectively (Fig. 2A). Since pilot trials 
investigating combinations of inhibitors of EGFR and mTOR are underway (Doherty 
et al., 2006; Reardon et al., 2006), this is of particular concern.  
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The widely held assumption that downstream effects of PI3K and Akt are necessarily 
mediated by mTOR is also challenged by the findings of Opel et al. who found that 
Akt activation is associated with decreased event-free or overall survival in 
neuroblastoma patients whereas phosphorylation of the prototypical mTOR target 
RPS6 is not (Opel et al., 2007). The same authors have recently reported that 
inhibition of mTOR fails to sensitize both PTEN wildtype and PTEN mutant human 
malignant glioma cells from established cell lines as well as from primary cultured 
glioblastoma samples towards cell death induced by TRAIL or chemotherapy, in line 
with our findings (Opel et al., 2008). Thus, at least for glioma cells, the current view of 
mTOR as an apoptosis-modulating target of Akt needs to be reconsidered.  
It is intriguing to speculate that the observed dissociation of hypoxia-protective effects 
and antiapoptotic effects on the level of mTOR could be due to effects of EGFR 
inhibition that are not mediated by impaired EGFR kinase function as recently 
described (Weihua et al., 2008). However, it is notable that the effects described by 
Weihua et al. were only observed with gene suppression, which reduces EGFR 
protein expression necessary for the function of the glucose transporter SGLT1, not 
with EGFR kinase inhibitors such as PD153035, which was employed in our study. 
The similar effects achieved with erlotinib support this conclusion (supplementary Fig. 
S1A and S1B). 
Further, both types of consequences of EGFR inhibition – protection from hypoxia, as 
well as enhanced apoptosis – can be mimicked by inhibitors of EGFR-dependent 
signal transduction. Co-inhibition of PI3K and MEK,  in contrast to co-inhibition of 
mTOR and MEK, sensitizes glioma cells towards CD95L (see Fig. 2A and 
supplementary Fig. S1C). Protection from hypoxia-induced cell death in cells co-
exposed to LY294002 and U0126 has previously been demonstrated (Steinbach et 
al., 2004).  
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The experiments with the Akt-specific inhibitor Akt inhibitor VIII further clarify the level 
of EGFR-dependent signal transduction that mediates the proapoptotic 
consequences (supplementary Fig. S2B, C)(DeFeo-Jones et al., 2005). Since 
inhibition of Akt also conferred protection from hypoxia (supplementary Fig. S2D), our 
data are well compatible with a dissociation of pro-apoptotic and hypoxia-protective 
effects downstream of Akt. A recent report implicates protein kinase C (PKC) as the 
mediator of EGFR signalling to mTOR independently of Akt, dissecting mTOR from 
the Akt-signalling cascade and challenging the widely held assumption of mTOR as a 
downstream target of Akt (Fan et al., 2009). In our experimental setting, however, Akt 
inhibition mimicked both the pro-apoptotic and the hypoxia-protective effects of 
EGFR inhibition whereas mTOR inhibition only mimicked the hypoxia-protective 
effects. Whether parallel rather than serial signal pathways are more relevant for 
regulation of mTOR by EGFR through Akt, PKC or both thus remains to be 
determined. We have incorporated our data and this new finding in a schematic 
drawing summarizing the proposed functions of signalling molecules in glioblastoma 
cells (supplementary Fig. S6). 
Even more striking than its lack of toxicity, mTOR antagonism exerts powerful 
cytoprotective effects on hypoxic glioma cells (Fig. 4B, C; Fig. 5G). mTOR is a 
master regulator of cellular energy homeostasis and, under physiologic conditions, 
reduced mTOR activity as a consequence of impaired nutrient availability enables 
cells to survive by adapting metabolic processes (Lee et al., 2007; Peng et al., 2002). 
Therefore, the hypoxia-protective effects of mTOR inhibition should not come entirely 
unexpected. Our results suggest that, in patients with malignant glioma, mTOR 
inhibition may jeopardize the antitumour effects of both spontaneously occurring 
tumour hypoxia and hypoxia resulting from antiangiogenic therapies and may 
contribute to adverse outcome. This hypothesis is based on studies demonstrating 
Deleted:  also
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that sublethal hypoxia is a major selective pressure driving and maintaining genetic 
instability and a mutator phenotype which leads to the selection of more aggressive 
tumour cell clones (Bristow and Hill, 2008) exhibiting therapy-resistance with reduced 
apoptotic potential (Graeber et al., 1996) and increased invasive properties 
(Pennacchietti et al., 2003). Hypoxia-protective effects of rapamycin have also been 
observed in mouse LLC cells (Hamanaka et al., 2005). The protection from hypoxia 
conferred by mTOR antagonism in conjunction with its lack of cytotoxicity may offer 
an explanation for the disappointing results of clinical trials with mTOR inhibitors for 
recurrent glioblastoma (Galanis et al., 2005). It may be prudent to consider 
undesirable effects originating from alterations of cellular metabolism and energy 
homeostasis for strategies targeting the EGFR-PI3K-Akt axis at any molecule, 
upstream (Steinbach et al., 2004) or downstream of mTOR. The validity of the 
assumption that the protection from hypoxia conferred by the inhibition of EGFR and 
mTOR could result in clinically relevant adverse effects is supported by recent data 
from clinical trials combining EGFR inhibition with antiangiogenetic agents. Lassen et 
al. (ASCO annual meeting 2008, abstract #2056) presented data from a trial with 
erlotinib in combination with bevacizumab and irinotecan in patients with progressive 
glioblastoma. Progression-free survival at 6 months in this one-armed trial was at a 
disappointing level of 24%, as compared with 48% in the original study with 
bevacizumab and irinotecan (Wagner et al., ASCO annual meeting 2008, abstract 
#2021). Overt antagonistic effects of the anti-EGFR antibody cetuximab were 
demonstrated in a randomized phase III trial comparing bevacizumab plus 
chemotherapy alone or combined with cetuximab in patients with colon cancer (Tol et 
al., 2008). Notably, the hypoxia-protective effect of EGFR inhibition in vitro is also 
detectable in colon carcinoma cells (S. Wolking, J. Rieger and J. P. Steinbach, 
unpublished data).  
Page 27 of 58
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 817 2040 ext. 167
Brain
For Peer Review
 
27 
The complexity of the metabolic response of human malignant glioma cells towards 
hypoxia is further illustrated by the dissociation of mTOR signalling and HIF-1 α. In 
non-transformed cells and some tumour cell lines, mTOR induces HIF-1 α expression, 
possibly via a posttranslational mechanism (Hudson et al., 2002). Given that hypoxia 
suppresses mTOR signalling in malignant glioma cells (Fig. 4A), this mechanism 
should result in reduced expression of HIF-1 α. However, levels of HIF-1 α protein 
were maintained in hypoxic mTORsh cells and cells exposed towards rapamycin (Fig. 
6E, F). One plausible explanation is that hypoxic glioma cells are under selective 
pressure to maintain HIF-1 α-dependent neoangiogenesis. Since HIF-1 α also exerts 
metabolic effects important for the adaptation of tumour cells to hypoxic conditions 
(Brahimi-Horn and Pouyssegur, 2007), the capability of glioma cells to maintain HIF-1 
α expression independently of mTOR may also be important for the rapamycin-
induced protection from hypoxic cell death. HIF-1 α -antagonistic strategies therefore, 
potentially, could revert mTOR inhibition-dependent resistance towards hypoxia. 
Finally, mTOR inhibition may have valuable anti-tumour effects that only become 
apparent in vivo. First, it has been shown that rapamycin specifically sensitizes 
U87MG cell xenografts towards radiotherapy while single layer cultures are not 
affected (Eshleman et al., 2002). Notably, in that study rapamycin failed to 
demonstrate in vivo growth-inhibitory effects in spite of the known antiproliferative 
effects in vitro and the probable antiangiogenic effects, again suggesting 
mechanisms of rapamycin resistance such as decreased susceptibility towards 
hypoxia. Further, rapamycin also has antiangiogenic properties, some of which may 
be dependent on HIF-1 α (Del Bufalo et al., 2006; Phung et al., 2007), whereas 
others may be dependent on direct cytotoxic effects of rapamycin on human 
endothelial cells (Barilli et al., 2008). These properties, in conjunction with the strong 
antiproliferative effects of rapamycin and its low toxicity as well as the successful 
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clinical trials of mTOR-inhibition for other tumour types, e.g., renal cell carcinoma, 
warrant further studies of mTOR inhibition in malignant glioma patients.  
A recently reported neoadjuvant trial of rapamycin treatment prior to scheduled 
resection of recurrent glioblastoma with PTEN loss followed by rapamycin 
maintenance therapy demonstrated that nanomolar concentrations of rapamycin can 
be achieved in glioblastoma (Cloughesy et al., 2008). The authors concluded that 
rapamycin reduced proliferation in patients with evidence of decreased RPS6 
phosphorylation. The median time to progression with adjuvant rapamycin therapy 
after surgery was only 99 days in this molecular enriched population, although there 
was some evidence of clinical activity. These results are well compatible with our 
finding of growth inhibition as the principal anti-tumour effect of rapamycin and 
suggest mechanisms of resistance towards rapamycin other than insufficient tumour 
penetration. 
Inhibition of mTOR may be most successful in the setting of primary therapy in 
combination with radiotherapy. The risk for a clinically relevant negative impact of the 
hypoxia-protective effects of mTOR inhibition would plausibly be lowest for patients 
who have undergone macroscopically complete resections of their tumours that 
should minimize the occurrence of hypoxia. These issues will be addressed in a 
forthcoming clinical study with the non-immunosuppressant mTOR Inhibitor CCI-779 
in combination with radiotherapy versus radiotherapy alone in the primary therapy of 
glioblastoma with unmethylated MGMT-promoter that will be conducted by the 
EORTC brain tumour group (W. Wick, personal information). 
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Figure legends 
 
Fig. 1. Concentration-dependent inhibition of S6K1 phosphorylation by rapamycin in 
human malignant glioma cells. 
LNT-229 or U87MG cells were exposed to vehicle or rapamycin (0.1-1000 nM) in 
serum-free medium for 20 min. Levels of phosphorylated and total S6K1 protein were 
analysed by immunoblot. 
 
Fig. 2. Effects of pharmacological manipulation of EGFR-Akt-mTOR signalling on 
CD95L- and chemotherapy-induced cell death. 
A, upper panel. LNT-229 or U87MG cells were exposed to vehicle, rapamycin (100 
nM), PD153035 (10 µM), LY294002 (10 µM) or U0126 (20 µM) alone or combined as 
indicated in serum-free medium for 20 min for immunoblot analysis. Cellular lysates 
were analysed for P-p90RSK, P-Akt, P-p42/44 MAPK, P-RPS6, eIF4E, P-4E-BP1 or 
4E-BP1. Lower panel. LNT-229 cells were exposed to 100 U/ml CD95L, U87MG cells 
were exposed to 20 U/ml CD95L for 24 h. Cell density was assessed by crystal violet 
staining, cell densities are normalised and shown as percentages of the cell densities 
when inhibitors were used as single agents or combinations without CD95L (n=3, * P 
< 0.05 corrected for multiple testing, student’s t-test). 
B, LNT-229 cells were co-incubated with vehicle or 100 nM rapamycin and exposed 
to CCNU or vincristine for 72 h. Cell density was assessed by crystal violet staining 
(n=3, all P-values were > 0.05, student’s t-test). 
 
Fig. 3. Effects of rapamycin on viability and proliferation. 
A, B, C, To assess proliferation, LNT-229 (A), or U87MG (B) cells and primary 
glioblastoma cultures (C) were exposed to vehicle or 100 nM rapamycin in serum-
Page 31 of 58
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 817 2040 ext. 167
Brain
For Peer Review
 
31 
free medium or medium containing 10% FCS. Cell density was assessed by crystal 
violet staining (n>3, * P < 0.05, ** P < 0.01, student’s t-test). The cell growth of 
vehicle-treated cells after 72 h corresponds to 100%. For viability analysis, cells were 
incubated in serum-free medium with rapamycin for 72 h. PI uptake was quantified by 
flow cytometry. The spontaneously occurring percentage of PI-positive cells was not 
enhanced by rapamycin. 
 
Fig. 4. Effects of rapamycin on hypoxia-induced cell death and hypoxia-induced 
alterations of mTOR signalling. 
A, LNT-229 cells were cultured in medium containing 10% FCS or in serum-free 
medium containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 
µM PD153035 under normoxia or hypoxia for 8 h as indicated. Cellular lysates were 
analysed with antibodies to P-p90RSK, P-Akt, P-p42/44 MAPK, P-RPS6, eIF4E, P-
S6K1, S6K1, P-4E-BP1, 4E-BP1 or actin. 
B, LNT-229 cells were incubated in serum-free medium containing 2 mM glucose and 
exposed to vehicle, 100 nM rapamycin or 10 µM PD153035 under normoxia or 
hypoxia for 20 h. Cytotoxicity was assessed by LDH release (n=4, n.s. P > 0.05, ** P 
< 0.01, student’s t-test). 
C, LNT-229 cells were pre-incubated for 24 h in serum-free medium with either 
vehicle or 100 nM rapamycin, followed by exposure to normoxia or hypoxia in serum-
free medium containing 2 mM glucose in the presence of rapamycin or vehicle for 20 
h. Hypoxia-induced cell death was assessed by LDH release (n=4, ** P < 0.01, 
student´s t-test). Note that the slightly higher amount of hypoxia-induced cell death in 
untreated cells compared to B is due to a higher cell growth. 
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Fig. 5. shRNA-mediated gene silencing of mTOR: effects on chemotherapy-induced 
cell death, proliferation and hypoxia-induced cell death. 
A, LNT-299 cells were transfected with either the empty pSUPER puro vector (puro) 
or the pSUPER puro plasmid with the mTOR-directed small hairpin sequence 
(mTORsh). Cellular lysates were analysed by immunoblot with antibodies to mTOR 
and actin. 
B, LNT-229 puro or mTORsh cells were incubated in serum-free medium for 24 h 
and subsequently exposed to serum-free medium containing 100 ng/ml EGF and 50 
ng/ml IGF-1 for 10 min. Cellular lysates were analysed by immunoblot with antibodies 
to P-4E-BP1, 4E-BP1 or actin. 
C, LNT-229 puro or mTORsh cells were incubated in serum-free medium for 23 h, 
then rapamycin was added to a final concentration of 100 nM. After 1 h cells were 
exposed to serum-free medium containing 100 ng/ml EGF and 50 ng/ml IGF-1 and 
100 nM rapamycin for 20 min. Cellular lysates were analysed by immunoblot with 
antibodies to P-4E-BP1 or actin. 
D, LNT-229 puro and mTORsh cells were incubated in medium containing 10% FCS 
or in serum-free medium containing 2 mM glucose under normoxia (N8) or hypoxia 
(H8) for 8 h as indicated. Cellular lysates were analysed with antibodies to P-p90RSK, 
P-Akt, P-p42/44 MAPK, P-RPS6 and eIF4E. 
E, LNT-229 puro and mTORsh cells were exposed to CCNU or vincristine in serum-
free medium for 72 h. Cell density was assessed by crystal violet staining (n=3, * P < 
0.05, ** P < 0.01, student’s t-test). 
F, LNT-229 puro and mTORsh cells were incubated in serum-free medium or 
medium containing 10% FCS and exposed to vehicle or 100 nM rapamycin for the 
indicated periods of time. Cell density was assessed by crystal violet staining (n=3, 
n.s. P > 0.05, * P < 0.05, ** P < 0.01, student’s t-test). 
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G, LNT-229 puro and mTORsh cells were incubated in serum-free medium 
containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 µM 
PD153035 in hypoxia for 20 h. Cytotoxicity was assessed by LDH release (n=4, * P < 
0.05, ** P < 0.01, student’s t-test). 
 
Fig. 6. Effects of rapamycin and mTOR gene suppression on energy homeostasis. 
A, LNT-229 puro or mTORsh cells were incubated in serum-free medium containing 
2 mM glucose and exposed to vehicle or 10 µM PD153035 under normoxia or 
hypoxia for 12 h. Cellular ATP (percent of normoxic controls) was determined by 
luciferase assay (n=4, ** P < 0.01, student’s t-test). 
B, LNT-229 cells were preincubated in serum-free medium with vehicle or 100 nM 
rapamycin for 24 h. Subsequently the cells were incubated in serum-free medium 
containing 2 mM glucose and exposed to vehicle or 100 nM rapamycin under 
normoxia or hypoxia for 12 h. Cellular ATP was determined by luciferase assay (n=3, 
* P < 0.05, student’s t-test). 
C, LNT-229 puro and mTORsh cells were incubated in serum-free medium 
containing 2 mM glucose under normoxia or hypoxia for 16 h. Mitochondrial 
membrane potential was determined by JC-1 staining and analysed by flow 
cytometry. 
D, LNT-229 puro or mTORsh cells were incubated in serum-free medium containing 
2 mM glucose under hypoxia for 4 h. Glucose concentration in the supernatant was 
determined enzymatically (n=4, n.s. P > 0.05, student’s t-test). 
E, LNT-229 cells were incubated in medium containing 10% FCS or in serum-free 
medium containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 
µM PD153035 under normoxia or hypoxia for 8 h. Cellular lysates were analysed by 
immunoblot with antibodies to HIF-1 α or actin. 
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F, LNT-229 puro or mTORsh cells were incubated in serum-free medium containing 2 
mM glucose under normoxia or hypoxia for 8 h. Cellular lysates were analysed by 
immunoblot with antibodies to HIF-1 α or actin. 
G, LNT-229 cells were incubated in medium containing 10% FCS or serum-free 
medium and exposed to vehicle or 100 nM rapamycin for 24 h. Cellular lysates were 
analysed by immunoblot with antibodies to cyclin D1 or actin. 
 
 
Figure legends - supplementary figures 
 
Fig. S1. Effects of erlotinib and reduced concentrations of LY294002 and U0126 on 
CD95L-induced cell death and effect of erlotinib on hypoxia-induced cell death. 
A, LNT-229 cells were exposed to vehicle or 10 µM erlotinib in the presence of 
vehicle or 100 U/ml CD95L for 24 h. Cell density was assessed by crystal violet 
staining, normalised and shown as percentages of the cell densities when vehicle or 
erlotinib were used as single agents without CD95L (n=3, ** P < 0.01, student’s t-test). 
B, LNT-229 cells were incubated in serum-free medium containing 2 mM glucose and 
exposed to vehicle or 10 µM erlotinib under hypoxia (1% oxygen) for 72 h. 
Cytotoxicity was assessed by PI staining (n=2, * P < 0.05, student’s t-test).  
C, LNT-229 cells were exposed to vehicle, 5 µM LY294002, or 10 µM U0126 or both 
in the presence of vehicle or 100 U/ml CD95L for 20 h. Cell density was assessed by 
crystal violet staining, normalised and shown as percentages of the cell densities 
when vehicle or inhibitors were used as single agents without CD95L (n=3, * P < 0.05 
corrected for multiple testing, student’s t-test). 
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Fig. S2. Effects of inhibition of Akt signalling on CD95L-, TRAIL- and hypoxia-induced 
cell death. 
A, LNT-229 cells were exposed to vehicle or Akt inhibitor VIII (0.1-10 µM) in serum-
free medium for 30 min. Levels of phosphorylated and total Akt protein were 
analysed by immunoblot. 
B, C, LNT-229 cells were exposed to vehicle, 100 nm rapamycin or 1 µM Akt inhibitor 
VIII in the presence of vehicle or 100 U/ml CD95L (A) or 1000 ng/ml TRAIL (B) for 24 
h. Cell density was assessed by crystal violet staining, normalised and shown as 
percentages of the cell densities when inhibitors were used as single agents without 
CD95L or TRAIL (n=3, ** P < 0.01, student’s t-test). 
D, LNT-229 cells were incubated in serum-free medium containing 2 mM glucose and 
exposed to vehicle or 1 µM Akt inhibitor VIII under hypoxia for 20 h. Cytotoxicity was 
assessed by PI staining, representative results of one of four reproductions are 
shown. 
 
Fig. S3. Effects of rapamycin on p42/44 MAPK and Akt phosphorylation. 
A, B, LNT-229 (A) and U87MG (B) cells were incubated in serum-free medium 
containing vehicle or 100 nM rapamycin for 1, 3, 6, 12 or 24 h. Cellular lysates were 
analysed with antibodies to P-Akt, Akt, P-p42/44 MAPK, p42/44 MAPK, P-RPS6, 
eIF4E and actin. 
 
Fig. S4. Effects of rapamycin on viability and proliferation of primary glioblastoma 
cultures. 
A, To assess proliferation primary glioblastoma cultures were exposed to vehicle or 
100 nM rapamycin in serum-free medium or medium containing 10% FCS. Cell 
density was assessed by crystal violet staining (n > 3, * P < 0.05, ** P < 0.01, 
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student’s t-test). The cell growth of vehicle-treated cells after 72 h corresponds to 
100%. For viability analysis, cells were incubated in serum-free medium with 
rapamycin for 72 h. PI uptake was quantified by flow cytometry. The spontaneously 
occurring percentage of PI-positive cells was not enhanced by rapamycin. 
B, To further assess proliferation, primary glioblastoma cultures were exposed to 
vehicle or 100 nM rapamycin in serum-free medium or medium containing 10% FCS 
for 48 h, then cells were pulsed with 1 µCi [methyl-3H]thymidine for additional 16 h. 
[Methyl-3H]thymidine incorporation was assessed by a liquid scintillation counter (n > 
3, * P < 0.05, ** P < 0.01, student’s t-test). 
 
Fig. S5. Effects of rapamycin on hypoxia-induced cell death. 
A, LNT-229 cells were incubated in serum-free medium containing 2 mM glucose and 
exposed to vehicle, 1, 10, 100, 1000 nM rapamycin or 10 µM PD153035 under 
hypoxia for 20 h. Cytotoxicity was assessed by LDH release (n = 4, * P < 0.05, ** P < 
0.01, student’s t-test). 
B, Primary glioblastoma cultures were incubated in serum-free medium containing 2 
mM glucose and exposed to vehicle, 100 nM rapamycin or 10 µM PD153035 under 
hypoxia for 20 h. Cytotoxicity was assessed by LDH release (n = 4, * P < 0.05, ** P < 
0.01, student’s t-test). 
 
Fig. S6. Schematic drawing summarizing the proposed functions of signalling 
molecules in glioblastoma cells. 
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